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Theuse of bone allografts is contraindicated in septic revision surgery due to the high risk of graft reinfection.Antibiotic release from
the graft may solve the problem and these combinations can theoretically be used for prevention or even therapy of infection. The
present study investigated whether amoxicillin, ciprofloxacin, and vancomycin alone or in combination with chitosan or alginate
are suitable for short-term or long-term bone coating. Human bone allografts were prepared from femoral head and lyophilized.
Antibiotic coating was achieved by incubating the grafts in antibiotic solution and freeze-drying again. Two biopolymers chitosan
and alginate were used for creating sustained-release implantable coatings and the drug release profile was characterized in vitro
by spectrophotometry. Using lyophilization with or without chitosan only resulted in short-term release that lasted up to 48 hours.
Alginate coating enabled a sustained release that lasted for 8 days with amoxicillin, 28 days with ciprofloxacin coating, and 50
days with vancomycin coating. Using only implantable biodegradable allograft and polymers, a sustained release of antibiotics was
achieved with ciprofloxacin and vancomycin for several weeks. Since the calculated daily release of the antibiotic was lower than
the recommended IV dose, the calcium alginate coated bone graft can support endoprosthesis revision surgery.
1. Introduction
Surgical treatment of musculoskeletal diseases relies increas-
ingly on the long-term implantation of foreignmaterials such
as bone substitutes, endoprosthesis, degradable scaffolds,
and plastic components (e.g., polymethyl methacrylate or
polyethylene). Since the immune system is not well adapted
to fight bacterial infection associated with these foreign
materials [1, 2], human allograft seems to be a logical choice as
scaffold after suitable preparation [3, 4], although septic com-
plications are becoming a growing concern for the orthopedic
community [5, 6]. Infection after total hip replacement is still
an unsolved issue; according to a clinical article, infection
occurred in 1.7% after primary procedures and in 3.2% after
revision procedures [7]. The quantification in another article
had different results; in the United States the overall infection
burden from 1990 to 2004 of hip arthroplasty was 0.88%; this
value increases annually at a rate of close to 5% [8]. Based
on another survey, from 145 patients with infection involving
total joint arthroplasty subsequent infection occurred in 19%
of the cases [9]. Due to the low metabolic rate of bone tissue
and the low permeation of the formed bacterial biofilm [10],
it is difficult to reach the required local concentration of
antibiotics whether it is applied systemically or as a local
formulation (e.g., block, sponge, implant, and bead) prepared
during surgery [11–14]. In general practice, local treatment
is typically applied to support systemic antibiotics and most
frequently used drugs include amoxicillin, cephalexin, gen-
tamycin, sulfamethoxazole, ciprofloxacin, and vancomycin
applied in cement [15–17], beads [17], and impregnated bone
[18–23]. In addition, off-label use of these antibiotics mixed
by hand with the carrier bone substitute is often performed
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Table 1: Technical requirements against a local antibiotic formulation in the 3 main categories of orthopedic use in endoprosthesis surgery.
Medical purpose
Probability
of
infection
Antibiogram Required length of localantibiotic treatment
Typical local antibiotic
formulation Reference
Primary
implantation
Prevention of infection
arising from contamination
at surgery or early
postoperation
0.5–2% Not available
1-2 days or until the surgical
site is open through
drainage
Antibiotic bone cement,
off-the-shelf [27–30]
Aseptic
revision
Prevention of infection
arising from either
contamination or a
low-grade infection
n/a
Not available,
or its
reliability is
low
1-2 days or until the surgical
site is open through
drainage. Longer if
low-grade infection is
suspected.
Antibiotic bone cement,
bone substitutes, freehand
use of local antibiotic
powder or solution
[27, 31]
Septic
revision
Eradication of bacterial
infection 100% Available Several weeks
Antibiotic bone cement,
freehand use of local
antibiotic powder or
solution. Bone substitutes
are contraindicated.
[18, 27,
31, 32]
when the required antibiotic-carrier combination is not
available off the shelf [24]. Whether the applied dose and
the release kinetics of such mixtures are optimal or at least
adequate for the intended purpose is unknown; however it is
still the best way a surgeon can deal with these challenging
situations.
The therapeutic goal of local antibiotic use in combi-
nation with endoprosthesis can be categorized into three
distinct case types: (1) prevention of early infection in a
primary prosthesis implantation procedure, (2) inhibiting of
infection at aseptic prosthesis revisions where the probability
of an already ongoing low-grade infection is high, and (3)
treatment of massive infections at septic revisions [25, 26].
These cases pose differing challenges for the antibiotics
summarized in Table 1.
It is evident that even if one focuses only on antibiotic
bone substitutes several formulations should be available
in order to meet these diverging criteria [36]. One way of
modifying the release kinetics of drugs in an implantable
formulation is to couple the active agent with biodegradable
polymers. Two well-known materials, which are frequently
used to form biodegradable coatings, are chitosan (Chi) and
sodium alginate (Na-Alg) [37, 38]. These biopolymers have
been investigated over a wide scale including the preparation
of fibers, nanoparticles, and even bone substitutes, thus
posing a very low risk of toxicity [39–41]. Chitosan is typically
prepared from shrimp-shell chitin with hydrolysis and is
only soluble in acidic media. It forms excellent films and
coatings and in case it is added to acidic forms of drugs it can
slow down release and degradation [42]. Alginate derivatives
such as alginic acid or sodium alginate are produced from
seaweed species. The main feature of sodium alginate is that
it is insoluble in acidic solutions and forms a biodegradable
film that can be turned into water insoluble calcium alginate
(Ca-Alg), which can act as a barrier for drug coatings.
The general view of the surgical community is that local
use of antibiotics without any carrier is only effective for
the first few days postoperatively; however this view is not
supported by reliable experimental data [14, 43].Theoretically
it can be hypothesized that fixation of the antibiotic with
physicochemical means such as freeze-drying or embedding
in polymer coatings may prolong the release of drugs [43];
however it is unknown if these procedures can meet the
requirements detailed in Table 1.
The present study investigated if amoxicillin, cipro-
floxacin, or vancomycin dried onto the surface of human
bone allografts alone or in combination with Chi or Ca-Alg
coating is suitable for preparing an antibiotic implant. We
further studied the characteristics (drug release and drug
load) of a short-term and a long-term release antibiotic
coating in vitro.
2. Materials and Methods
All chemicals were purchased from Sigma except for van-
comycin, which was purchased from Hangzhou APIChem
Technology Co., Ltd., China. The HCl salt was used in case
of vancomycin and ciprofloxacin; however amoxicillin was
used in the trihydrate form. The bone blocks were generous
gifts from theWest-Hungarian Regional Tissue Bank. Freeze-
dried femoral head blocks were cut to 0.05 ± 0.01 g cube-
shaped pieces for the experiments.
Antibiotics were used in aqueous solutionswith the initial
concentrations of 0.1, 1, or 10mg/mL for preliminary exper-
iments. After evaluating these concentrations, we decided to
use a 10mg/mL starting solution for all further experiments
in order to obtain data with low signal-to-noise ratio. The
bone graft was placed in 1mL of the antibiotic solution and
the system was incubated at 25∘C for 24 hours. Subsequently,
the soaked graft was removed from the solution and freezed
at −80∘C followed by lyophilization for 24 hours using a
Labconco Freezone 2.5󸀠 freeze-dryer (soaked preparation).
In order to maximize the drug content of the graft an
alternative approach was also performed when the grafts
were frozen while still being submerged in the antibiotic
solution and the whole system was freeze-dried (saturated
preparation).
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Figure 1: Antibiotic coating methods. As a first step, 50mg bone allografts were incubated in a 10mg/mL antibiotic solution for 24 hours.
The Chi used for coating was 2 weight %; the alginate was 4 weight %. The final step in each method was lyophilization or drying in an oven
resulting in a dry bone allograft which looks the same to the naked eye as a regular uncoated graft.
Medium molecular weight Chi was used with a deacety-
lation grade of 75–85%, and the Chi solution prepared in our
experimental set-up contained lactic acid (LA, 90%) with a
ratio of 360 𝜇L LA/40mL 2% Chi.The chitosan-based prepa-
rations were prepared by using 1mL aqueous 2% chitosan
solution to dissolve the antibiotic. The bone samples were
placed in this solution and incubated at room temperature for
24 hours and frozen and lyophilized afterwards in a similar
manner as the saturated preparations.
Alginate-based preparations were created in another way
since this polymer exhibits a basic pH and antibiotics typi-
cally precipitate in this solution. First, the bone grafts were
coated by the saturated freeze-dried method as described
above; then a film coating of alginate was created on top of
the antibiotic layer. The Na-Alg film was prepared by adding
1mL4%Na-Alg solution on the antibiotic coated freeze-dried
bone.Then the graft was dried in an oven at 40∘C for 4 hours
on teflon plates. The process was repeated with the dried
coated graft turned upside down; thus the double layer Na-
Alg film was formed. Sodium alginate was then converted
into calciumalginate byCaCl
2
.TheNa-Alg coated bone grafts
were placed in a 10% CaCl
2
solution for exactly 60 seconds,
then washed with distilled water, and dried in an oven at
40∘C. The methods for preparing the coatings are presented
in Figure 1.
The chosen antibiotics (amoxicillin, ciprofloxacin, and
vancomycin) have characteristic absorbances in theUV range
in aqueous solutions, allowing the use of UV spectroscopy
to assess the concentrations with a spectrophotometer. The
Table 2: UVmeasurement characteristics of the investigated antibi-
otics.
Characteristic
absorbance (nm)
Linear
absorbance-concentration
interval
Amoxicillin 229 0.22–3.7
Ciprofloxacin 275 0.085–2.29
Vancomycin 280 0.06–2.00
absorbance-concentration diagrams were plotted using all
antibiotics and the linear phase of this diagram was used to
calculate the concentration from the absorbances according
to the Lambert-Beer law (Table 2).
We conducted preliminary experiments on the possible
absorbance of the used polymers; neither Na-Alg nor Chi
had detectable spectral peaks where the antibiotics were
measured, specifically 229 nm and 275–280 nm, and neither
had a significant baseline absorbance even in the maximum
possible concentrations used in the present protocol (0.1%
Na-Alginate or 0.25% chitosan). In contrast, Ca-Alginate was
insoluble in water and the precipitate would have made the
specific measurements impossible in case it had been present
in the supernatant.
Measurements of release kinetics were performed by
incubating each sample separately in 2mL of water in a 24-
well plate at room temperature. We did not work at 37∘C
to prevent evaporation and we did not use buffers to avoid
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Figure 2: Drug release kinetic of amoxicillin, ciprofloxacin, or vancomycin coating, prepared by the soaked or the saturated method. These
procedures are not expected to significantly increase release time, so over 90% of the drug is released within the first day.
changes in the solubility and adding possible UV absorbent
molecules. Concentration measurements were performed at
specified intervals by removing the supernatant for spec-
troscopy and replenishing with fresh solvent. The frequency
of solution changes and the length of the experiments were
determined by preliminary experiments and set in ways that
optimal kinetic curves could be constructed from the data
set. In the case of vancomycin and ciprofloxacin samples
were taken on the 1st, 5th, 10th, 15th, 20th, 25th, and
28th day. Vancomycin was also measured on the 50th day.
In a separate experiment with Ca-Alg coated amoxicillin
grafts, the medium was placed back onto the graft after
each measurement in order to evaluate the effect of drug
accumulation in themedium. Statisticswere carried out using
GraphPad Prism 5.0 software. All data were expressed as
means ± SEM (𝑛 = 3) and were analyzed using Student’s 𝑡-
test, simple analysis of variance (ANOVA), or 2-way ANOVA
with Bonferroni’s multiple comparison. Differences were
considered significant when 𝑃 < 0.05 (∗), 𝑃 < 0.01 (∗∗),
𝑃 < 0.001 (∗∗∗) (Table 3).
3. Results
After preliminary experiments (data not shown), all the three
drugs were highly soluble in water and were suitable to
be stored at room temperature without any decomposition.
The original concentration of the antibiotic solutions used
to incubate the bone grafts correlated with the amount of
antibiotics on the bone surface as estimated by the total
amount of drugs released. We decided to use a 10mg/mL
starting solution for all further experiments in order to obtain
data with low signal-to-noise ratio.
Simple freeze-drying of antibiotics on the surface of bone
grafts did not result in a sustained release of the compounds.
Although minor differences were observed among the three
antibiotics, each one is completely released within 48 hours
Table 3: The daily released amount of amoxicillin measured with
either replacing the solvent daily or replenishing the solvent. There
were significant differences in the 1st and 2nd day with the different
methods.
Released
drug
(mg/day)
Amoxicillin
solvent replenishment
Amoxicillin
cumulative release
Mean ± SEM Mean ± SEM
Day 1∗∗ 0.260 ± 0.037 0.168 ± 0.030
Day 2∗∗∗ 0.202 ± 0.026 0.098 ± 0.005
Day 3 0.081 ± 0.015 0.085 ± 0.016
Day 4 0.049 ± 0.013 0.063 ± 0.009
Day 5 0.032 ± 0.012 0.042 ± 0.012
Day 6 0.007 ± 0.002 0.021 ± 0.015
Day 7 0.003 0.001 ± 0.001
Day 8 0.003 0.002
∗∗ is the difference between the released drug on the first day with the two
different methods, and ∗∗∗ is the difference between the released drug on the
second day with the two different methods.
(Figure 2). Maximizing the antibiotic loading with the sat-
urated method did not improve the release kinetics only;
the overall amount of antibiotics on the graft was higher
(Figure 2(b)). Using a chitosan additive with the antibiotics
did not significantly prolong the release of the drugs from the
surface.
With the use of a Ca-Alg film layer, it was possible
to reach a long-term sustained-release antibiotic coating.
Interestingly, the type of antibiotic significantly affected the
rate of drug release from the same type of coating. For
example, amoxicillin was completely released within 8 days
and ciprofloxacin within 28 days while vancomycin exhibited
the longest release time with 50 days (Figure 3). The amount
of antibiotic released on the first day from Ca-Alg coated
allograft was approximately the same as the amount from
the antibiotic coated bones which did not contain Ca-Alg
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Figure 3: Release profile of amoxicillin, ciprofloxacin, or van-
comycin with sustained release Ca-Alg film coating (𝑛 = 3).
Although the coating method was the same in each case, the
effective release term was different among the three drugs with
amoxicillin lasting up to 8 days and ciprofloxacin up to 28 days while
vancomycin reached 50 days.
(Figure 2). The total quantity of dissolved antibiotics over
the 8-, 28-, or 50-day period depending on the respective
antibiotic was approximately the same as those without
alginate coating. We therefore conclude that the amount of
total antibiotic content did not increase; however, the release
rate has changed as shown in Figure 3.
In order to test whether the release kinetic is affected by
the negative feedback of drug accumulation in the solution,
we compared two sets of bone grafts either with release
in fresh solvent or with cumulative release into the same
medium. Ca-Alg coated amoxicillin was selected for this
measurement since it showed a significant change for several
days, while the other preparations had too slow or too fast
kinetics for this type ofmeasurement.Weobserved that above
the dosage of 0.1mg/day the release is slightly inhibited by the
accumulation of the compound; however this was no issue at
lower doses and did not affect the length of the active release
period either (Table 3).
To summarize the long-term release experiment, alto-
gether 0.64 ± 0.07mg amoxicillin was eluted from the surface
of 50mg bone allograft with complete dissolution in 8 days.
In case of ciprofloxacin, 1.08 ± 0.11mg was the total eluted
amount within 28 days. Vancomycin had the longest elution
time for over 50 days during which 1.66 ± 0.31mg antibiotic
was released in total.
4. Discussion
The present study indicated that it is possible to pro-
duce antibiotic coating with physicochemical methods. With
biopolymers we can modify the release kinetics of antibiotic
impregnated bone grafts in order to reach either complete
unloading in 48 hours or sustained release for up to 50 days.
A critical limitation in one-stage revision surgery is the
extent of bone loss. Ideally, one would perform elaborate
bone replacement techniques in order to build a suitable
biological base for a new implant; however bone grafts are
viewed as contraindicated in these procedures due to the high
probability of infection. Impregnation of bone grafts with an
antibiotic solution by hand mixing is generally applied in the
OR as a preventive measure; however most surgeons would
consider this technique inadequate for septic cases.This view
is confirmed by data from the present study. Even though the
antibiotics were incubated for a day and then freeze-dried
onto the bone, the majority of the drug (90%) was released
during the first day after placing the graft inwater.This release
kinetic may be suitable for fighting perioperative infection
when the implant may be contaminated during surgery
or from the patient’s skin through the surgical wound or
drainage tubes, but this timeframe is inadequate to eradicate
massive infections.
The amount of antibiotics in combination with a bone
substitute is a challenge. In most cases the volume of the
required bone graft is only determined during surgery and
predetermining the required dose is only realistic with
large margins. Moreover, the amount of antibiotic which
is implanted into a patient is set by the amount of bone
graft, as administering the drug follows the “dosing” of the
graft.The highly variable spatial conformations add a further
degree of freedom to the equation. One would assume that
tightly impacted bone chips between a cortical layer and a
metal implant have much lower surface for the body fluid
to penetrate than a porous block placed into a well bleeding
spongiotic area. Our current measurements showed that the
negative feedback from the accumulation of the drug in
a small volume just marginally affects the release kinetics.
Therefore the spatial effect probably plays a limited role in this
question. However, it should be noted that our experiment
was performed in a laboratory setting and release kinetics
with bodily fluids in the presence of metabolizing cells and
bacteria will be different. Therefore, due to the uncertainties
inherent in this applicable field, it is best to load bone grafts
with only a low amount of antibiotics to prevent overdosing.
As a comparison in the present study, we estimated the total
daily doses potentially released frombone graftswith selected
combinations. We applied the femoral head graft as a more
or less standard “dose” of bone grafting material frequently
applied in orthopedics. For these calculations we estimated
the antibiotic elution from a femoral head based on the results
from our experiments (Table 4.). In principle we multiplied
the antibiotic content based on the femoral head andour bone
chip weight ratio (45 g/0.05 g).
Please note that these calculations are based on data
gained in vitro, so these can only be considered as rough
estimates.The calculations show that the implantation of one
femoral head coated with any of the analyzed antibiotics can
release a significant percentage of the daily IV dose during
the first day but the dose goes below 10% in the long term.
Therefore, in case of large antibiotic bone grafts implanted, it
is recommended to set the systemic antibiotic dosing based
on close monitoring of serum levels for a few days after
surgery. Ciprofloxacin has to be monitored especially closely
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Table 4: Calculated antibiotic content of the coated bone compared to the daily doses in clinical practice.
24 hours from 0.05 g
bone
28th day from 0.05 g
bone
24 hours from 45 g
bone
28th day from 45 g
bone
Daily dose/reference
(mg/day)
Amoxicillin (mg) 0.26 234
6000 [33]% of daily dose 0.004 3.9
Ciprofloxacin (mg) 0.674 0.015 606.72 13.03
1500 [34]% of daily dose 0.045 0.001 40.45 0.87
Vancomycin (mg) 0.485 0.05 436.87 44.68
1000 [35]% of daily dose 0.049 0.005 43.687 4.468
as it has the highest cytotoxic effect among the three drugs
[44, 45]. A 10mg/mL starting concentration of antibiotic was
applied in our study and is also relevant according to the
literature of local antibiotic drug release products regarding
both amoxicillin [33, 46] and vancomycin [47]. We suggest
that these calculations may have some relevance towards
other antibiotic bone substitutes as well.
The release of the antibiotics was comparable or even
faster whenwe used chitosan than in the absence of a polymer
coating. Although Chi is a well-known vehicle for drugs,
and it was already applied in combination with vancomycin,
mostly with microencapsulation by spray drying [48–50],
we did not find it effective in our experiments. This can be
explained with our freeze-dried formulation and the solubil-
ity of chitosan. This polymer is only soluble in acidic media
and the three chosen drugs were also acids or acidic salts. We
speculate that the acidic drugs enhanced the solubility of Chi,
since most antibiotics are also acids, and the use of chitosan
as a delivery vehicle for sustained release is not suitable.
Ca-Alg was used as a layer by layer film coating, and
in most cases alginate is used in loaded beads [51] or
microspheres [52] or composites [53]. Since all the three
drugswe used precipitated in theNa-Alg solution, we decided
to use it as a coating to separate the drugs from water. The
long-term release was successful when we produced a water
insoluble Ca-Alg film coating. Due to the uneven surface of
the bone structure, the thickness of the alginate film cannot be
proven to be uniform on the surface of the bone. According
to our current results this did not affect the elution charac-
teristics. Although the coating exhibited little difference for
amoxicillin, both ciprofloxacin and vancomycin proved to be
suitable for sustained release bone graft formulations. The
drug delivery period of at least 28 days should be sufficient for
the long-term antibacterial effect required for the eradication
of implant-related infections [54]. Loading biomaterials with
antibiotic is nowadays a standard medical procedure for the
local treatment or prevention of bacterial infection. However,
there are concerns related to biofilm formation, developing
resistance especially if the local antibiotic cement is the first
line treatment [55]. One possible solution is that different
antibiotics should be added locally than in the preventive
phase or two or more antibiotics should be combined in local
treatment [56]. Bacterial biofilm formation on bone cement
has also been studied; adhesion to the bone cement is an
important factor [57]. However, there is no evidence that
an alginate coating on bone allograft would be suitable for
biofilm formation. On the other hand, prevention of bacterial
resistance can be solved with the use of combined drug
coating later on in the in vitro experiments. Besides, we also
have to keep in mind that both the allograft and the alginate
coating are biodegradable, which can pose an obstruction for
biofilm formation. According to our measurements, the MIC
value of vancomycin was 0.2 𝜇g/mL for Enterococcus faecalis
(data not shown) and the MIC value of 2 𝜇g/mL vancomycin
is sufficient against vancomycin susceptible MRSA [58–60].
Taking into account that using our coating and vancomycin
as the antibiotic wemanaged to keep the released vancomycin
concentration above 5𝜇g per mL at the 50th day, the in vitro
results show that this drug coated biomaterial is capable of
keeping the antibiotic above the required dose for a prolonged
time.
5. Conclusion
We conclude that sustained release antibiotic bone graft
coating can be achieved by using an insoluble Ca-Alg coating
on bone allografts impregnated with antibiotics. This prepa-
ration allows the sustained release of either vancomycin or
ciprofloxacin at therapeutic levels for at least 28 days, making
this composition suitable for septic revision surgery. A short-
term release coating without the protective alginate layer is
also possible, especially with amoxicillin, a broad-spectrum
antibiotic regularly used for the prevention of infection [33,
46].
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